AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
Is the FDA Too Cautious?
Open to Debate
The FDA's Accelerated Approval of the Alzheimer Drug
FDA gave accelerated approval to a drug where the evidence wasn't there, and their own advisory committee voted against it. The problem is that studies take a long time to get done; moreover, drugs do come to market and they turn out to be non-confermatory. "The issue in the FDA is not to approve or not approve fast or not," says Dr. Colin Rieckhoff.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode